AG
KURA icon

Artal Group’s Kura Oncology KURA Stock Holding History

Artal Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,819,884
Closed -$37.5M – 52
2024
Q2 		$37.5M Sell
1,819,884
-100,000
-5% -$2.06M 0.96% 15
2024
Q1 		$41M Buy
1,919,884
+151,828
+9% +$2.95M 1.04% 14
2023
Q4 		$25.4M Sell
1,768,056
-250,000
-12% -$2.46M 0.85% 19
2023
Q3 		$18.4M Hold
2,018,056
– – 0.79% 20
2023
Q2 		$21.4M Buy
2,018,056
+300,000
+17% +$3.55M 0.66% 23
2023
Q1 		$21M Buy
1,718,056
+18,056
+1% +$225K 1.25% 22
2022
Q4 		$21.1M Buy
1,700,000
+600,000
+55% +$8.72M 1.18% 29
2022
Q3 		$15M Buy
1,100,000
+50,000
+5% +$771K 0.64% 33
2022
Q2 		$19.2M Hold
1,050,000
– – 1.03% 24
2022
Q1 		$16.9M Hold
1,050,000
– – 0.71% 33
2021
Q4 		$14.7M Hold
1,050,000
– – 0.4% 56
2021
Q3 		$19.7M Buy
1,050,000
+450,000
+75% +$8.48M 0.44% 53
2021
Q2 		$12.5M Hold
600,000
– – 0.25% 79
2021
Q1 		$17M Hold
600,000
– – 0.3% 72
2020
Q4 		$19.6M Buy
600,000
+50,900
+9% +$1.79M 0.42% 58
2020
Q3 		$16.8M Sell
549,100
-28,900
-5% -$638K 0.41% 53
2020
Q2 		$9.42M Buy
578,000
+178,000
+45% +$2.57M 0.26% 73
2020
Q1 		$3.98M Hold
400,000
– – 0.17% 82
2019
Q4 		$5.5M Buy
400,000
+150,000
+60% +$2.22M 0.21% 69
2019
Q3 		$3.79M Buy
+250,000
New +$4.45M 0.15% 80
2018
Q2 		– Sell
-100,000
Closed -$1.88M – 112
2018
Q1 		$1.88M Hold
100,000
– – 0.02% 95
2017
Q4 		$1.53M Hold
100,000
– – 0.02% 104
2017
Q3 		$1.5M Buy
+100,000
New +$939K 0.03% 100

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's KURA Position: Q3 2024 in Review

Artal Group sold out of Kura Oncology (KURA) in Q3 2024, closing a stake of 1,819,884 shares — an estimated $37.5M sold.

Artal Group first reported a position in KURA in Q3 2017 and held it in 23 quarters. The position peaked at $41M in Q1 2024. 179 funds tracked by Wall St. Rank hold KURA as of Q3 2024.

  • Artal Group reported no remaining Kura Oncology position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,819,884 Kura Oncology shares in Q3 2024, an estimated $37.5M.
  • Artal Group first reported a position in Kura Oncology in Q3 2017 and held it in 23 quarters.
  • Artal Group's Kura Oncology position peaked at $41M in Q1 2024.
  • 179 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.